Advisor Resource Council’s BioMarin Pharmaceuticals BMRN Stock Holding History

Advisor Resource Council’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,427	Closed	-$234K	–	264
2023 Q4	$234K	Buy	+2,427	New	+$215K	0.03%	414
2022 Q3	–	Sell	-2,427	Closed	-$201K	–	191
2022 Q2	$201K	Buy	+2,427	New	+$193K	0.02%	483
2022 Q1	–	Sell	-3,800	Closed	-$336K	–	251
2021 Q4	$336K	Buy	+3,800	New	+$314K	0.03%	406
2021 Q3	–	Sell	-3,925	Closed	-$328K	–	249
2021 Q2	$328K	Buy	+3,925	New	+$311K	0.03%	378

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Advisor Resource Council's BMRN Position: Q1 2024 in Review

Advisor Resource Council sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 2,427 shares — an estimated $234K sold.

Advisor Resource Council first reported a position in BMRN in Q2 2021 and held it in 4 quarters. The position peaked at $336K in Q4 2021. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

Advisor Resource Council reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Advisor Resource Council sold 2,427 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $234K.
Advisor Resource Council first reported a position in BioMarin Pharmaceuticals in Q2 2021 and held it in 4 quarters.
Advisor Resource Council's BioMarin Pharmaceuticals position peaked at $336K in Q4 2021.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Advisor Resource Council's 13F filing for Q1 2024, filed 19 Apr 2024.